Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Begins Trading on Nasdaq

NEW YORK (GenomeWeb News) — Rosetta Genomics began trading on the New York Stock Exchange today at $7 per share with a total of 3.75 million shares.
The company’s bid price opened today at $7.02 and by mid-afternoon had climbed almost 7 percent to $7.50.


The Israeli company, which will trade on the Nasdaq Global Market under the symbol "ROSG," stated that set price in a release this morning before the opening bell.
It also said underwriters would have a 30-day option to buy as many as 562,500 shares to cover over-allotments.
When Rosetta filed with its initial public offering with the US Securities and Exchange Commission in September 2006, the company said it expected to sell 3 million shares priced between $11 and $13, which would have generated just under $45 million.
Last month, Rosetta lowered that price to between $7.50 and $8.50 in an amended filing, which would raise a total of around $30 million through the IPO and the over-allotment.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.